ECSP11011204A - Compuestos de quinazolina sustituidos - Google Patents

Compuestos de quinazolina sustituidos

Info

Publication number
ECSP11011204A
ECSP11011204A EC2011011204A ECSP11011204A ECSP11011204A EC SP11011204 A ECSP11011204 A EC SP11011204A EC 2011011204 A EC2011011204 A EC 2011011204A EC SP11011204 A ECSP11011204 A EC SP11011204A EC SP11011204 A ECSP11011204 A EC SP11011204A
Authority
EC
Ecuador
Prior art keywords
methods
kinase
diseases
mediated disorder
substituted quinazoline
Prior art date
Application number
EC2011011204A
Other languages
English (en)
Inventor
David Middlemiss
Caroline Leriche
Eric Auclair
Roux Jacques Le
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of ECSP11011204A publication Critical patent/ECSP11011204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se dirige a ciertos compuestos novedosos, métodos para producirlos y métodos para tratar o mejorar un trastorno mediado por cinasa. Más particularmente, esta invención se dirige un compuestos de quinazolina sustituidos útiles como inhibidores de cinasa selectivos, métodos para producir tales compuestos y métodos para tratar o mejorar un trastorno mediado por cinasa, En particular, los métodos se relacionan con el tratamiento o mejora de un trastorno mediado por cinasa que incluye enfermedades cardiovasculares, diabetes, trastornos asociados con diabetes, enfermedades inflamatorias, trastornos inmunológicos, cáncer y enfermedades de los ojos tales como retinopatías o degeneración macular u otras enfermedades vitreorretinianas, y similares.
EC2011011204A 2008-12-29 2011-07-14 Compuestos de quinazolina sustituidos ECSP11011204A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29

Publications (1)

Publication Number Publication Date
ECSP11011204A true ECSP11011204A (es) 2011-10-31

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011204A ECSP11011204A (es) 2008-12-29 2011-07-14 Compuestos de quinazolina sustituidos

Country Status (23)

Country Link
US (1) US8389530B2 (es)
EP (1) EP2381943A1 (es)
JP (1) JP2012514020A (es)
KR (1) KR20110120878A (es)
CN (1) CN102333533A (es)
AU (1) AU2009334869A1 (es)
BR (1) BRPI0924067A2 (es)
CA (1) CA2748319A1 (es)
CO (1) CO6390105A2 (es)
CR (1) CR20110368A (es)
DO (1) DOP2011000209A (es)
EA (1) EA019110B1 (es)
EC (1) ECSP11011204A (es)
IL (1) IL213742A0 (es)
MA (1) MA32968B1 (es)
MX (1) MX2011007064A (es)
NI (1) NI201100134A (es)
NZ (1) NZ593949A (es)
PE (1) PE20120424A1 (es)
SG (1) SG172415A1 (es)
TN (1) TN2011000319A1 (es)
WO (1) WO2010076238A1 (es)
ZA (1) ZA201104777B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
RU2679130C2 (ru) 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
HUE059037T2 (hu) 2013-10-25 2022-10-28 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
MX2017008518A (es) 2014-12-24 2017-10-25 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038315A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
AU2004281154A1 (en) 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
CA2578283A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2600531A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
JP5079500B2 (ja) * 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
BRPI0606172A2 (pt) 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン

Also Published As

Publication number Publication date
AU2009334869A1 (en) 2011-07-14
IL213742A0 (en) 2011-07-31
CR20110368A (es) 2011-12-02
SG172415A1 (en) 2011-07-28
TN2011000319A1 (en) 2012-12-17
MA32968B1 (fr) 2012-01-02
DOP2011000209A (es) 2011-09-30
AU2009334869A2 (en) 2011-09-29
NI201100134A (es) 2012-03-06
WO2010076238A1 (en) 2010-07-08
US20120004210A1 (en) 2012-01-05
PE20120424A1 (es) 2012-05-04
MX2011007064A (es) 2012-01-20
NZ593949A (en) 2013-08-30
CO6390105A2 (es) 2012-02-29
US8389530B2 (en) 2013-03-05
CA2748319A1 (en) 2010-07-08
EA201101012A1 (ru) 2012-01-30
CN102333533A (zh) 2012-01-25
EA019110B1 (ru) 2014-01-30
ZA201104777B (en) 2012-03-28
JP2012514020A (ja) 2012-06-21
BRPI0924067A2 (pt) 2016-01-26
EP2381943A1 (en) 2011-11-02
KR20110120878A (ko) 2011-11-04

Similar Documents

Publication Publication Date Title
ECSP11011204A (es) Compuestos de quinazolina sustituidos
CO6420343A2 (es) [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
CY1124311T1 (el) Παρεμποδιστες dna-pk
CO6660505A2 (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
CR20110103A (es) Heteroarilos sustituidos
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
PH12015501806A1 (en) Novel benzopyran kinase modulators
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
NI201000214A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4.
WO2012125408A8 (en) Pegylated apelin and uses thereof
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
CL2019001091A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
CL2011001845A1 (es) Uso de un agente terapeutico en el talamo mediante distribucion por conveccion mejorada (ced) para tratar un trastorno neurologico cortical.
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
BR112013033836A2 (pt) terapia de combinação
AU2013328979A8 (en) Compounds for treating Rac-GTPase mediated disorder
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
AR122753A2 (es) Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas